Background
==========

With the introduction of highly active antiretroviral therapy (HAART) more than a decade ago, the incidence of *Pneumocystis jiroveci*pneumonia (PCP) \[[@B1]\] has decreased significantly in the Western hemisphere. However, PCP still remains the most common opportunistic infection in patients infected with the human immunodeficiency virus (HIV) \[[@B2]\]. Among patients with HIV infection and PCP the mortality rate is 10 to 20% during the initial infection and increases substantially with the need for mechanical ventilation \[[@B3]\]. In 1990 an expert panel recommended the use of corticosteroids for HIV-infected patients with PCP and substantial hypoxemia (initial arterial oxygen partial pressure of \<70 mmHg or alveolar-arterial gradient \>35 mmHg on room air) based on the evidence from five randomised controlled trials \[[@B4]\]. This consensus statement still represents the basis of current treatment guidelines \[[@B5]\]. However, at the time this statement was made, one trial was not yet completed \[[@B6]\], two trials were stopped prematurely \[[@B7],[@B8]\], and one trial was not published in full \[[@B9]\]. In 1992 a systematic review qualitatively summarised the same incomplete data \[[@B10]\].

We present an updated systematic review and meta-analysis of randomised controlled trials to assess the magnitude of effects of adjunctive corticosteroid therapy on overall mortality and the need for mechanical ventilation in HIV-related PCP. In addition, we provide numbers needed to treat that may serve as estimates for the expected benefit of adjunctive corticosteroid therapy in the presence and absence of HAART.

Methods
=======

Search for relevant studies
---------------------------

We searched MEDLINE (January 1985 -- December 2004), EMBASE (January 1985 -- December 2004) and the Cochrane Library (issue 4, 2004) without language restrictions to identify randomised controlled trials that compared adjunctive corticosteroids to control in HIV-infected patients with PCP. We used the terms *steroid\*, corticosteroid\*, glucocorticoid\*, pneumocystis, PCP, \*carinii, \*jiroveci*as text words and *Glucocorticoids, Adrenal Cortex Hormones, Steroids, Pneumocystis Infections, Pneumocystis jiroveci*, and *Pneumonia, Pneumocystis*as Medical Subject Headings. We restricted the search to articles indexed as randomised controlled trials (publication type) or drug therapy (subject heading) or those that included the words *random\**or *placebo*in their titles or abstracts. We further reviewed the reference lists from previously published overviews \[[@B4],[@B10]\], we searched UptoDate version 2005 and Clinical Evidence Concise (issue 12, 2004), contacted experts of the field, and searched reference lists of identified publications for citations of additional relevant articles.

Study selection and data abstraction
------------------------------------

Trials were considered eligible for this meta-analysis if they compared corticosteroids to placebo or usual care in HIV-infected patients with PCP in addition to baseline treatment with trimethoprim-sulfamethoxazole, pentamidine or dapsone-trimethoprim, used random allocation, and reported mortality data. We excluded trials in patients with no or mild hypoxemia (arterial oxygen partial pressure \>70 mmHg or an alveolar-arterial gradient \<35 mmHg on room air) and trials with a follow-up of less than 30 days.

Two teams of investigators (MB/HCB and RB/HF) assessed study eligibility and quality blinded to one another\'s rating and resolved any disagreement by consensus. Data of eligible trials were abstracted in duplicate. We assessed the quality of included trials with respect to concealment of treatment allocation; blinding of patients, caregivers or assessors of clinical outcomes; performance of a sample size calculation; and if the trial was stopped early \[[@B11]\]. The main endpoint for benefit of adjunctive corticosteroid therapy was overall mortality. A secondary endpoint was the need for mechanical ventilation.

Statistical analysis
--------------------

All analysis was according to the intent-to-treat principle. We pooled treatment effects across studies and calculated a weighted average risk ratio of overall mortality in the treatment and control groups by using a random effects model. We investigated the presence of publication bias by means of funnel plots \[[@B12]\]. We tested for heterogeneity with the Cochran Q test and measured inconsistency (I^2^; the percentage of total variance across studies that is due to heterogeneity rather than chance) of treatment effects across studies \[[@B13],[@B14]\]. We carried out sensitivity analyses to examine treatment effects according to quality components of trials, and if publication was as a peer-reviewed article or just in abstract form. Numbers needed to treat were calculated by multiplying the mean relative risk reduction with an initial mean baseline risk \[[@B15]\]. All statistical analyses were performed using Stata 8.2 (StataCorp, College Station, Tex).

Results
=======

We identified 8 trials \[[@B6]-[@B9],[@B16]-[@B19]\] that met our inclusion criteria (Figure [1](#F1){ref-type="fig"}). We excluded one trial \[[@B17]\] because it investigated only patients with mild hypoxemia and had a very short follow-up of only 3 days, and another trial \[[@B18]\] which turned out to be a subgroup analysis of a larger included trial \[[@B8]\] \[see [Additional file 1](#S1){ref-type="supplementary-material"}\]. In total, there were 242 individuals in the intervention and 247 individuals in the control groups. The Funnel plot indicated no evidence for a publication bias (Figure [2](#F2){ref-type="fig"}). Characteristics of included trials are provided in Table [1](#T1){ref-type="table"}.

![Flow diagram of trials. RCT, randomised controlled trial.](1471-2334-5-101-1){#F1}

![Funnel plot to evaluate the presence of a publication bias in trials investigating adjunctive corticosteroids for pneumocystis jiroveci pneumonia in HIV-infected patients. The funnel graph plots the log of the treatment odds ratio against the standard error (s.e.) of the log odds ratio (an indicator of sample size). Open circles represent trials included in the meta-analysis. The line in the centre indicates the summary log odds ratio. In the absence of a publication bias, the log odds ratio estimates from smaller trials are expected to be scattered above and below the summary estimate, producing a symmetric triangular or funnel shape. When smaller trials with larger log odds ratios are missing, the funnel plot appears asymmetric and may indicate the presence of a publication bias. In our systematic review the funnel plot looks symmetric. The Egger test for publication bias was not statistically significant (*P*= 0.91).](1471-2334-5-101-2){#F2}

###### 

Characteristics of included trials

  **Author (year) reference**     **Diagnosis of PCP**             **Baseline treatment for PCP**                 **Oxygenation entry criteria**   **Corticoid (route)/initial daily dose/duration (days)**   **Interval (max.) \***   **Blinding patients/care givers/assessors**   **Concealed allocation/n centres**   **Sample size calculation/stopped early**   **Randomised individuals to I/C**   **Total deaths in I/C**
  ------------------------------- -------------------------------- ---------------------------------------------- -------------------------------- ---------------------------------------------------------- ------------------------ --------------------------------------------- ------------------------------------ ------------------------------------------- ----------------------------------- -----------------------------------
  Clement et al. (1989) \[9\]     BAL, sputum                      88% TMP-SMX, 12% Pentamidine                   PaO~2~\<51 mmHg (room air)       Methylprednisolon (IV)/240 mg/8 d                          Unlimited                Yes/Yes/Unclear                               Unclear/1                            Unclear/No                                  19/22                               9/9 at 56 days
  Montaner et al. (1990) \[8\]    BAL                              TMP-SMX, Pentamidine, Dapsone-TMP              85--90% O~2~-Saturation †        Prednisone (oral)/60 mg/7 d with 14 d tapering             48 h                     Yes/Yes/Unclear                               Yes/1                                Yes/Yes                                     18/19                               1/0 at 30 days 2/1 at 90 days
  Bozzette et al. (1990) \[16\]   75% BAL, 15% sputum + presumed   80% TMP-SMX, 18% Pentamidine, 2% Dapsone-TMP   Hypoxemia ratio \>75 ‡           Prednisone (oral)/80 mg/21 d or as baseline treatment      36 h                     No/No/Unclear                                 Yes/6                                Yes/No                                      123/128                             13/28 at 31 days 20/33 at 84 days
  Gagnon et al. (1990) \[7\]      BAL, biopsy, sputum              TMP-SMX                                        PaO~2~\<75 mmHg (35% oxygen)     Methylprednisolon (IV)/160 mg/7--10 d                      72 h                     Yes/Yes/Unclear                               Unclear/1                            Yes/Yes                                     12/11                               3/9 at 28 days 5/9 at 120 days
  Nielsen et al. (1992) \[6\]     BAL, biopsy                      TMP-SMX                                        PaO~2~\<67.5 mmHg (room air)     Methylprednisolon (IV)/2 mg/kg/10 d                        24 h                     No/No/Unclear                                 Unclear/3                            Unclear/Yes                                 30/29                               2/9 at 34 days 4/9 at 90 days
  Walmsley et al. (1995) \[19\]   BAL, biopsy, sputum              82% TMP-SMX, 17% Pentamidine, 1% Dapsone-TMP   PaO~2~\<70 mmHg (room air) §     Methylprednisolon (IV)/80 mg/10 d                          24 h                     Yes/Yes/Unclear                               Yes/3                                Yes/No                                      40/38                               4/6 at 35 days

Abbreviations: PCP, *Pneumocystis jiroveci*pneumonia; n, number; I/C, intervention/control group; BAL, bronchoalveolar lavage; TMP, trimethoprim; SMX, sulfamethoxazole; IV, intravenous.

\* Maximal interval between initiation of baseline treatment for *Pneumocystis jiroveci*pneumonia and initiation of corticosteroid.

† Or 5% decrease on exercise.

‡ PaO~2~divided by fraction of inspired oxygen.

§ Or alveolar-arterial oxygen gradient \>40 mmHg if arterial blood gases could not be assessed on room air.

Overall mortality
-----------------

Risk ratios for overall mortality were significantly reduced for adjunctive corticoids at 1 month (0.54;95% CI, 0.38--0.79) and at 3--4 months (0.67;95% CI, 0.49--0.93) of follow-up (Figure [3](#F3){ref-type="fig"}). We found some evidence for heterogeneity among trials at 1 month (test of heterogeneity, *P*= 0.12; I^2^= 43% \[95% uncertainty interval \[UI\], 0%--78%\]) whereas at 3--4 months treatment effects looked more homogenous (*P*= 0.46; I^2^= 0% \[95% UI, 0%--75%\]. In a sensitivity analysis heterogeneity was considerably reduced when the analysis was limited to trials with early (\<3 days) adjunctive corticosteroids that were published in full, i.e. excluding Clement et al. \[[@B9]\] (summary risk ratio for mortality at 1 month: 0.45 (95% CI, 0.29--0.70), heterogeneity *P*= 0.49; I^2^= 0% \[95% UI, 0%--79%\]). In further sensitivity analyses for the mortality endpoint at 1 month summary risk ratios were 0.55 (95% CI, 0.32--0.93) in trials that reported concealed allocation \[[@B8],[@B16],[@B19]\], 0.74(95% CI, 0.45--1.21) in trials reporting blinding of patients and care-givers \[[@B7]-[@B9],[@B19]\], and 0.64 (95% CI, 0.42--0.98) in trials not prematurely halted \[[@B9],[@B16],[@B19]\].

![Summary estimates for overall mortality at 1 month (A) and 3--4 months (B) follow-up. The Cochran Q test for heterogeneity. I^2^as a measure of inconsistency (in percent). CI indicates confidence interval; UI, uncertainty interval.](1471-2334-5-101-3){#F3}

Need for mechanical ventilation
-------------------------------

Reliable data on the need for mechanical ventilation was only available for the 3 largest trials \[[@B6],[@B16],[@B19]\]. Again, the risk ratio for this endpoint was largely reduced in the group with early adjunctive corticosteroids (0.37;95% CI, 0.20--0.70; *P*= 0.40; I^2^= 0% \[95% UI, 0%--90%\]).

Discussion
==========

This systematic review of 6 randomised controlled trials in HIV-infected patients with PCP and substantial hypoxemia found a significant relative risk reduction of death for adjunctive corticosteroids of 46% at 1 month and of 33% at3--4 months. The average-weighted mean mortality in control groups of included trials at one month was 25%. This initial mortality-rate of 25% can be assumed in settings where HAART is not available which is still the case for most developing countries \[[@B20]\]. In this situation we estimated that 9 (95% CI, 6--19) HIV-infected patients with PCP have to be treated early with adjunctive corticosteroids to prevent 1 death during the first month after PCP diagnosis. In Western countries, where HAART is widely available, the respective number to treat was estimated to be 22 (95% CI, 16--48) patients assuming an initial mortality rate of 10% \[[@B21]\]. With regard to the need for mechanical ventilation the risk reduction for adjunctive corticosteroids was even greater in the investigated patient population, but the number of trials was small (n = 3).

Our study has several strengths and limitations. We conducted an extensive literature search to retrieve all eligible trials. However, formal testing for publication bias was not very powerful because of a relatively small number of included trials. Even with a symmetric looking funnel plot, such bias cannot be ruled out. Moreover, with a small number of included trials the uncertainty interval for the inconsistency among trials may not be very informative \[[@B13]\]. We focused mainly on mortality data that may be less prone to ascertainment bias, and we analysed the data according to the intent-to-treat principle to get more conservative estimates. Finally, the trials included in this meta-analysis used different corticosteroid regimen. So far, neither the dosing nor the length and tapering schedule of corticosteroids has been addressed adequately in randomised trials. In current recommendations \[[@B5]\] the corticosteroid schedule of the largest trial \[[@B16]\] was adapted.

There has been some concern among physicians treating patients with AIDS that further immunosuppression due to corticosteroid therapy could accelerate the onset of other HIV-related opportunistic complications \[[@B22],[@B23]\]. However, with the exception of an increase in muco-cutaneous herpes simplex infection episodes \[[@B16]\], adjunctive corticosteroids were not associated with an increase in opportunistic complications in any of the included trials. A large cohort study which used a standard 21-day tapering course of adjunctive corticosteroids found no difference in the risk of AIDS-related complications apart from an increase in esophageal candidiasis \[[@B24]\].

It is possible that adjunctive corticosteroids are also beneficial for HIV-infected patients with mild hypoxemia due to PCP \[[@B17]\]. However, in this situation the short term mortality is low and possible unfavourable effects of corticosteroids might outweigh the benefits. Moreover, corticosteroids might also be beneficial for non-HIV-infected patients with severe PCP \[[@B25]\], but evidence from randomised controlled trials is still lacking.

Conclusion
==========

This meta-analysis confirmed and quantified the benefit of adjunctive corticosteroid therapy in HIV-infected patients with moderate-severe PCP. We estimated a relative risk reduction for overall mortality of 46% at 1 month and 33% at 3--4 months. We calculated numbers needed to treat of 9 patients for settings without HAART, and 22 patients with HAART available to prevent 1 death. Our results underline the conclusions of the early released consensus statement \[[@B4]\], and support current recommendations for the management of PCP in HIV-infected patients \[[@B5]\].
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